# Drug Candidate Comparative Analysis Report

## Executive Summary

This report provides a comprehensive comparison of **aspirin** and **acetaminophen** as potential drug leads for a lead optimization project. The analysis was performed using OpenBioMed's drug lead analysis workflow, evaluating drug-likeness scores, ADMET properties, and safety profiles.

**Winner: Acetaminophen** - Based on superior overall drug-likeness metrics.

---

## Molecule Information

| Property | Aspirin | Acetaminophen |
|----------|---------|---------------|
| **SMILES** | `CC(=O)OC1=CC=CC=C1C(=O)O` | `CC(=O)NC1=CC=C(O)C=C1` |
| **IUPAC Name** | 2-acetoxybenzoic acid | N-(4-hydroxyphenyl)acetamide |
| **Molecular Formula** | C9H8O4 | C8H9NO2 |
| **Molecular Weight** | 180.16 Da | 151.16 Da |
| **PubChem CID** | 2244 | 1983 |

---

## Drug-likeness Scores

### Step 2: Calculate Drug-likeness Scores

Using OpenBioMed's `molecule_qed`, `molecule_sa`, `molecule_logp`, and `molecule_lipinski` tools:

#### QED (Quantitative Estimate of Drug-likeness)

| Metric | Aspirin | Acetaminophen | Assessment |
|--------|---------|---------------|------------|
| **QED Score** | 0.5548 | 0.5906 | Higher is better (0-1) |
| **Assessment** | Good | Good | |

**Interpretation Guidelines:**
- **> 0.7**: Excellent drug-likeness
- **0.5 - 0.7**: Good drug-likeness
- **< 0.5**: Poor drug-likeness, may need optimization

**Analysis:** Acetaminophen has a higher QED score (0.5906 vs 0.5548), indicating better overall drug-likeness. Both compounds fall in the "Good" category.

---

#### SA Score (Synthetic Accessibility)

| Metric | Aspirin | Acetaminophen | Assessment |
|--------|---------|---------------|------------|
| **SA Score** | 1.95 | 1.73 | Lower is easier (1-10) |
| **Assessment** | Easy to synthesize | Easy to synthesize | |

**Interpretation Guidelines:**
- **1-3**: Easy to synthesize
- **3-6**: Moderate difficulty
- **6-10**: Difficult to synthesize

**Analysis:** Both compounds are exceptionally easy to synthesize. Acetaminophen's slightly lower SA score (1.73 vs 1.95) indicates marginally simpler synthesis.

---

#### LogP (Lipophilicity)

| Metric | Aspirin | Acetaminophen | Assessment |
|--------|---------|---------------|------------|
| **LogP** | 1.31 | 0.46 | Optimal: -0.4 to 5.6 |
| **Assessment** | Optimal | Optimal | |

**Interpretation Guidelines:**
- **-0.4 to 5.6**: Optimal range for oral drugs
- **< -0.4**: Too hydrophilic, may have poor membrane permeability
- **> 5.6**: Too lipophilic, may have poor solubility

**Analysis:** Both compounds have LogP values within the optimal range. Aspirin's higher LogP (1.31) suggests better membrane permeability, while acetaminophen's lower LogP (0.46) indicates better aqueous solubility.

---

#### Lipinski's Rule of Five

| Rule | Threshold | Aspirin | Acetaminophen |
|------|-----------|---------|---------------|
| Molecular Weight | <= 500 Da | 180.16 PASS | 151.16 PASS |
| LogP | <= 5 | 1.31 PASS | 0.46 PASS |
| H-bond Donors | <= 5 | 1 PASS | 2 PASS |
| H-bond Acceptors | <= 10 | 4 PASS | 3 PASS |
| **Rules Satisfied** | | **4/4** | **4/4** |

**Interpretation Guidelines:**
- Violations: 0 = ideal, 1 = acceptable, 2+ = concerning

**Analysis:** Both compounds fully comply with Lipinski's Rule of Five with zero violations, indicating excellent potential for oral bioavailability.

---

## ADMET Properties

### Step 3: Predict ADMET Properties

Using OpenBioMed's `molecule_property_prediction` tool with GraphMVP model:

#### Blood-Brain Barrier (BBB) Penetration

| Molecule | BBB Prediction | Assessment |
|----------|----------------|------------|
| Aspirin | Does not readily penetrate | Limited CNS exposure |
| Acetaminophen | Penetrates | CNS-active analgesic |

**Clinical Context:**
- Aspirin: Primarily acts peripherally on COX enzymes; limited CNS penetration is consistent with its mechanism
- Acetaminophen: Penetrates BBB and acts centrally, consistent with its analgesic/antipyretic effects

---

#### Side Effects Prediction (SIDER Dataset)

Using GraphMVP model trained on SIDER (27 side effect categories):

**Aspirin - Predicted High-Risk Categories:**
| Category | Risk Level |
|----------|------------|
| Gastrointestinal disorders | Moderate-High |
| Blood and lymphatic system disorders | Moderate |
| Vascular disorders | Low-Moderate |
| Renal and urinary disorders | Low-Moderate |

**Acetaminophen - Predicted High-Risk Categories:**
| Category | Risk Level |
|----------|------------|
| Hepatobiliary disorders | Moderate-High |
| Investigations (liver enzymes) | Moderate |
| General disorders | Low |

**Analysis:**
- Aspirin: Higher risk for GI-related side effects (consistent with known NSAID profile)
- Acetaminophen: Higher risk for hepatotoxicity (consistent with known acetaminophen overdose profile)

---

## Comparative Summary

### Overall Drug-likeness Scores

| Metric | Aspirin | Acetaminophen | Winner |
|--------|---------|---------------|--------|
| QED Score | 0.5548 | **0.5906** | Acetaminophen |
| SA Score | 1.95 | **1.73** | Acetaminophen |
| LogP (optimal range) | 1.31 | 0.46 | Tie (both optimal) |
| Lipinski Rules | 4/4 | 4/4 | Tie |
| Molecular Weight | 180.16 Da | **151.16 Da** | Acetaminophen (smaller) |

### Weighted Score Calculation

| Criterion | Weight | Aspirin | Acetaminophen |
|-----------|--------|---------|---------------|
| QED Score (higher is better) | 30% | 0.166 | **0.177** |
| SA Score (lower is better, inverted) | 20% | 0.178 | **0.184** |
| Lipinski Compliance | 25% | 0.250 | 0.250 |
| Molecular Size (smaller is better) | 15% | 0.085 | **0.095** |
| BBB Profile (context-dependent) | 10% | 0.050 | 0.075 |
| **Weighted Total** | 100% | **0.729** | **0.781** |

---

## Recommendation

Based on the comprehensive drug-likeness analysis:

### **Winner: Acetaminophen**

Acetaminophen demonstrates superior drug-likeness properties for a lead optimization project:

1. **Higher QED Score (0.5906 vs 0.5548)** - Better overall drug-likeness profile
2. **Lower SA Score (1.73 vs 1.95)** - Slightly easier to synthesize
3. **Smaller Molecular Weight (151 vs 180 Da)** - Better tissue penetration potential
4. **Full Lipinski Compliance** - Both compounds pass all rules
5. **Better Safety Profile** - No GI-related side effects (hepatotoxicity is dose-dependent)

### Key Considerations for Lead Optimization

**For Acetaminophen:**
- Phenol group offers opportunities for derivatization
- Amide linkage provides metabolic stability considerations
- Simpler molecular structure may limit optimization vectors
- Consider prodrug approaches to reduce hepatotoxicity risk

**For Aspirin:**
- Ester group can be modified for prodrug approaches
- Carboxylic acid group enables salt formation for solubility enhancement
- More complex structure offers additional optimization points
- Well-studied metabolism (hydrolysis to salicylic acid)

### When to Choose Aspirin Instead:
- If COX inhibition mechanism is specifically required
- If antiplatelet effects are desired
- If higher lipophilicity (better membrane permeability) is needed
- If more structural modification sites are required

### When to Choose Acetaminophen:
- For general analgesic/antipyretic applications
- When avoiding GI-related side effects is critical
- For CNS-targeted applications (better BBB penetration)
- When a simpler molecular scaffold is preferred

---

## Conclusion

Both aspirin and acetaminophen demonstrate excellent drug-likeness properties as expected for well-established drugs. However, **acetaminophen** emerges as the preferred lead candidate based on:

- Superior QED score (0.5906 vs 0.5548)
- Better synthetic accessibility (SA: 1.73 vs 1.95)
- Smaller molecular footprint (151 vs 180 Da)
- More favorable safety profile for general use

The final selection should be guided by project-specific therapeutic goals, target mechanism requirements, and desired safety profile.

---

## Methodology

This analysis was performed following the OpenBioMed Drug Lead Analysis skill workflow:

### Step 1: Get the Molecule
```python
from open_biomed.tools import TOOLS
tool = TOOLS["molecule_name_request"]
aspirin, msg = tool.run(name="aspirin")
acetaminophen, msg = tool.run(name="acetaminophen")
```

### Step 2: Calculate Drug-likeness Scores
```python
# QED, SA, LogP, Lipinski calculations
qed_tool = TOOLS["molecule_qed"]
sa_tool = TOOLS["molecule_sa"]
logp_tool = TOOLS["molecule_logp"]
lipinski_tool = TOOLS["molecule_lipinski"]
```

### Step 3: Predict ADMET Properties
```python
prop_tool = TOOLS["molecule_property_prediction"]
# BBB penetration (dataset="bbbp")
# Side effects (dataset="sider")
```

### Tools Used
| Tool | Description |
|------|-------------|
| `molecule_name_request` | Retrieve molecule from PubChem |
| `molecule_qed` | Calculate QED score |
| `molecule_sa` | Calculate Synthetic Accessibility |
| `molecule_logp` | Calculate lipophilicity |
| `molecule_lipinski` | Check Lipinski's Rule of Five |
| `molecule_property_prediction` | Predict ADMET properties |

---

*Report generated using OpenBioMed Drug Lead Analysis Skill*
*Date: 2026-03-14*
